nach oben

Tumor Biology

Erschienen in:

01.04.2014 | Research Article

Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma

verfasst von: Ting Liu, Zeyuan Lei, ZhengYing Pan, Yu Chen, Xiang Li, TongChun Mao, Qian He, Dongli Fan

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

This study was designed to obtain a conclusive result about the relevance of p53 codon 72 polymorphism to the risk of cutaneous squamous cell carcinoma (SCC). We performed an updated meta-analysis of 3,792 subjects (1,349 cancer cases and 2,443 controls) to summarize the data available for p53 codon 72 polymorphism and SCC risk. The association was estimated by odds ratios (ORs) with 95 % confidence intervals (CIs). The meta-analysis showed no statistical significance for SCC risk associated with any of the genetic models of p53 codon 72 polymorphism. The analyses by ethnic subgroup also failed to produce significant associations. This study suggests that p53 codon 72 polymorphism does not appear to represent a significant susceptibility factor for SCC in Caucasians.

Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.PubMedCrossRef

Mueller CS, Reichrath J. Histology of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:215–26.PubMedCrossRef

Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146 Suppl 61:1–6.PubMedCrossRef

Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327(23):1649–62.PubMedCrossRef

Rees J. Genetic alterations in non-melanoma skin cancer. J Invest Dermatol. 1994;103(6):747–50.PubMedCrossRef

Tilli CM et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152(6):1108–24.PubMedCrossRef

Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin. 2003;53(5):292–302.PubMedCrossRef

Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794–8.PubMedCentralPubMedCrossRef

Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49–53.PubMedCrossRef

10.

Thomas M et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–100.PubMedCentralPubMed

11.

Dumont P et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRef

12.

Henner WD et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001;49(4):263–6.PubMedCrossRef

13.

Wu X et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94(9):681–90.PubMedCrossRef

14.

Fan R et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1037–42.PubMed

15.

Soulitzis N et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179(2):175–83.PubMedCrossRef

16.

Shen H et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183(2):123–30.PubMedCrossRef

17.

Helland A et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396(6711):530–1. author reply 532.PubMedCrossRef

18.

Andersson S et al. The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer. 2001;85(8):1153–6.PubMedCentralPubMedCrossRef

19.

Dokianakis DN et al. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.PubMed

20.

Marshall SE et al. p53 codon 72 polymorphism and susceptibility to skin cancer after renal transplantation. Transplantation. 2000;69(5):994–6.PubMedCrossRef

21.

Bastiaens MT et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog. 2001;30(1):56–61.PubMedCrossRef

22.

Cairey-Remonnay S et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol. 2002;118(6):1026–31.PubMedCrossRef

23.

McGregor JM et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol. 2002;119(1):84–90.PubMedCrossRef

24.

Gustafsson AC et al. The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. Acta Derm Venereol. 2004;84(6):439–44.PubMedCrossRef

25.

Han J et al. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog. 2006;45(9):694–700.PubMedCrossRef

26.

Bendesky A et al. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res. 2007;619(1–2):38–44.PubMedCrossRef

27.

Almquist LM et al. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis. 2011;32(3):327–30.PubMedCentralPubMedCrossRef

28.

Loeb KR et al. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One. 2012;7(4):e34422.PubMedCentralPubMedCrossRef

29.

Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRef

30.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

31.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef

32.

Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRef

33.

Jiang DK et al. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011;131(1):220–8.PubMedCrossRef

Titel: Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma
verfasst von: Ting Liu
Zeyuan Lei
ZhengYing Pan
Yu Chen
Xiang Li
TongChun Mao
Qian He
Dongli Fan
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1518-0

Springer Medizin

Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Polymorphisms of the XPC gene may contribute to the risk of head and neck cancer: a meta-analysis

Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye

Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer

Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie